Fusion Pharmaceuticals Inc. clinical trials
Acquired by AstraZeneca, Jun 4, 2024 · source ↗
The registry lists 5 studies whose lead sponsor is Fusion Pharmaceuticals Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 6, 2026.
- 5studies on the registry
- 0open to participants now
- 2reach primary completion within a year
Before and after it joined AstraZeneca
- First submitted before Fusion Pharmaceuticals Inc. became part of AstraZeneca
- 4
- First submitted after Fusion Pharmaceuticals Inc. became part of AstraZeneca
- 1
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Fusion Pharmaceuticals Inc.’s studies test, most studies first; none is open now — 3 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
Coming up
2 of Fusion Pharmaceuticals Inc.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- 1DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- 1MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- NNov
All 2
- Dec 2026FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)actinium zadavotide guraxetan AC-225 · NCT06402331
- May 2027FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)actinium zadavotide guraxetan AC-225 · NCT06909825
Add all 2 to your calendar (.ics) → With an account.
All 5 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 119
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Fusion Pharmaceuticals Inc.5 studies
Something wrong with this grouping? Tell us on the AstraZeneca page.
Studies
Recruiting first, then most recently updated. Showing 5 of 5. All AstraZeneca studies →
- FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)Active, not recruitingNCT06909825Phase 2
Sponsor listed in the registry: Fusion Pharmaceuticals Inc. · First submitted after Fusion Pharmaceuticals Inc. became part of AstraZeneca
- FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)Active, not recruitingNCT06402331Phase 2
Sponsor listed in the registry: Fusion Pharmaceuticals Inc. · First submitted before Fusion Pharmaceuticals Inc. became part of AstraZeneca
- Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).Active, not recruitingNCT05219500Phase 2
Sponsor listed in the registry: Fusion Pharmaceuticals Inc. · First submitted before Fusion Pharmaceuticals Inc. became part of AstraZeneca
- A Phase 1 Study of [225Ac]-FPI-1434 InjectionTerminatedNCT03746431Phase 1
Sponsor listed in the registry: Fusion Pharmaceuticals Inc. · First submitted before Fusion Pharmaceuticals Inc. became part of AstraZeneca
- A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid TumoursTerminatedNCT05363605Phase 1/2
Sponsor listed in the registry: Fusion Pharmaceuticals Inc. · First submitted before Fusion Pharmaceuticals Inc. became part of AstraZeneca